Conditions: Carcinoma, Non-small Cell
Keywords: lung cancer adenocarcinoma HER2
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 119
Healthy volunteers: no

Brief summary:
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.

Detailed description:

Arms:
arm 1: Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC arm 2: Dacomitinib in patients with HER2 mutated or amplified NSCLC

Interventions: intervention 1: Dacomitinib (PF-00299804) intervention 2: Dacomitinib (PF-00299804)
Intervention descriptions: intervention 1: Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose). intervention 2: In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.

Protocol document: